SEHK:2628
SEHK:2628Insurance

Evaluating China Life Insurance (SEHK:2628)’s Valuation After RMB5 Billion Real Estate Commitment

China Life Insurance (SEHK:2628) has been back on investors’ radar after committing an extra RMB5 billion to its flagship real estate partnership, tightening the link between its investment portfolio and long term insurance liabilities. See our latest analysis for China Life Insurance. The extra commitment to its Beijing real estate project comes on top of November’s strong premium update and tighter asset management governance. The market has taken notice, with the share price at HK$28.8 and...
SEHK:175
SEHK:175Auto

Geely Automobile (SEHK:175) Valuation Check After Launching a 10% Share Buyback Program

Geely Automobile Holdings (SEHK:175) has kicked off a sizable share buyback, with approval to repurchase up to 10% of its stock. This move can tighten supply and lift per share metrics over time. See our latest analysis for Geely Automobile Holdings. The buyback kicks in as the share price sits at HK$16.96, with a solid year to date share price return of around 20% but a softer 1 year total shareholder return of 12.8%. This suggests momentum is firming but not euphoric. If you like Geely’s...
SEHK:1918
SEHK:1918Real Estate

Sunac China (SEHK:1918) Valuation Check as Offshore Debt Restructuring Nears Key Completion Step

Sunac China Holdings (SEHK:1918) is back on investors radar as its long running offshore debt overhaul nears a key milestone, with markets eyeing the effective date of its multi billion dollar restructuring plan. See our latest analysis for Sunac China Holdings. The debt overhaul narrative is now clearly showing up in the tape, with the share price at HK$1.31 after a steep year to date share price return of minus 42.29 percent and a one year total shareholder return of minus 46.31 percent...
SEHK:512
SEHK:512Pharmaceuticals

Grand Pharmaceutical Group (SEHK:512) Valuation After Phase II Success for Innovative TCM Depression Treatment

Grand Pharmaceutical Group (SEHK:512) just cleared a key hurdle. Its TCM antidepressant candidate GPN01360 hit the primary endpoint in a Phase II trial in China, reinforcing the company’s push into broader chronic disease markets. See our latest analysis for Grand Pharmaceutical Group. The market seems to be taking notice, with the latest 1 day share price return of 2.63 percent lifting Grand Pharmaceutical Group to HK$8.19. Its year to date share price return of 78.04 percent and three year...
SEHK:2145
SEHK:2145Personal Products

Asian Growth Companies With High Insider Ownership December 2025

As Asian markets navigate a landscape marked by mixed economic signals and evolving monetary policies, investors are increasingly focusing on companies that demonstrate resilience and growth potential. In this context, stocks with high insider ownership often stand out as they can indicate strong management confidence and alignment with shareholder interests, making them attractive considerations in uncertain times.
SEHK:2145
SEHK:2145Personal Products

3 Asian Stocks That Investors Might Be Undervaluing By Up To 35.8%

As the Bank of Japan raises its benchmark interest rate to the highest level in 30 years and Chinese markets show mixed signals, investors are closely watching for opportunities within Asia's evolving economic landscape. In this environment, identifying undervalued stocks can be crucial, as they may offer potential value when market conditions stabilize or improve.
SEHK:669
SEHK:669Machinery

Will Exiting HART to Emphasize Milwaukee and Ryobi Change Techtronic Industries' (SEHK:669) Narrative

Earlier this month, Techtronic Industries Company Limited said it will voluntarily discontinue its HART business by the end of 2025, while retaining the HART brand in its portfolio and reporting that Milwaukee and Ryobi point-of-sale demand remained firm through November. The move highlights Techtronic’s sharper focus on higher-margin core franchises, suggesting a continued tilt toward businesses where demand and profitability are strongest. We’ll now examine how exiting the HART business,...
SEHK:817
SEHK:817Real Estate

Assessing China Jinmao Holdings Group (SEHK:817)’s Valuation After Its November 2025 Contracted Sales Update

China Jinmao Holdings Group (SEHK:817) just released its unaudited contracted sales for November 2025, giving investors a fresh look at how its development pipeline is converting into actual cash-flow-generating deals. See our latest analysis for China Jinmao Holdings Group. That solid contracted sales update lands against a mixed backdrop, with a 30 day share price return of minus 16.33% and a year to date share price return of 29.47%. The 1 year total shareholder return of 31.93% contrasts...
SEHK:6069
SEHK:6069Diversified Financial

SY Holdings Group (SEHK:6069) Valuation After Expanding Guarantees to Back Supply Chain Finance Growth

SY Holdings Group (SEHK:6069) just doubled down on its core supply chain finance engine by extending and enlarging guarantees and loans to key affiliates through 2027, a balance sheet commitment big enough to trigger Hong Kong Listing Rules disclosure. See our latest analysis for SY Holdings Group. That backdrop helps explain why investors have largely leaned in this year, with the share price climbing strongly, reflected in a 57.72% year to date share price return and a 64.32% one year total...
SEHK:9633
SEHK:9633Beverage

Evaluating Nongfu Spring (SEHK:9633) After HSBC’s Upgrade on New RTD Tea and Coffee Growth Prospects

HSBC’s upgrade of Nongfu Spring (SEHK:9633) from Hold to Buy has put fresh attention on the stock, with the bank highlighting new sugar ready to drink teas and Tan Bing branded coffees as growth drivers. See our latest analysis for Nongfu Spring. The upgrade lands after a choppy stretch, with a 30 day share price return of minus 6.8 percent and a 90 day share price return of minus 12.7 percent. However, a strong year to date share price return of 43.3 percent and a 1 year total shareholder...
SEHK:6855
SEHK:6855Biotechs

Assessing Ascentage Pharma (SEHK:6855) Valuation After New ASH 2025 Hematology Data on Olverembatinib and Lisaftoclax

Ascentage Pharma Group International (SEHK:6855) just used the 67th ASH Annual Meeting as a showcase, rolling out fresh long term data on Olverembatinib and Lisaftoclax that further clarifies the story behind the stock. See our latest analysis for Ascentage Pharma Group International. The latest ASH data land after a bumpy stretch, with a 30 day share price return of minus 11.8 percent and a 90 day share price return of minus 25.1 percent. However, a much stronger year to date share price...
SEHK:322
SEHK:322Food

Tingyi (Cayman Islands) Holding (SEHK:322): Valuation Check After Major CEO Transition Announcement

Tingyi (Cayman Islands) Holding (SEHK:322) has kicked off a major leadership transition, with long serving CEO Chen Yinjang set to retire at the end of 2025 and Wei Hong Chen stepping in from January 2026. See our latest analysis for Tingyi (Cayman Islands) Holding. The leadership handover comes as Tingyi’s 90 day share price return of 11.55 percent and year to date share price return of 21.22 percent signal improving momentum. A 1 year total shareholder return of 29.75 percent shows the...
SEHK:2600
SEHK:2600Metals and Mining

Aluminum Corp of China (SEHK:2600) Valuation After New Energy High-Precision Foil Expansion Moves

Aluminum Corporation of China (SEHK:2600) just shook things up with a completed capital contribution to Yunnan Aluminum Foil, backing a new energy high precision sheet, strip, and foil project that sharpens its high end growth trajectory. See our latest analysis for Aluminum Corporation of China. The move into high precision new energy materials comes after a strong run, with Aluminum Corporation of China’s share price returning around 51% over 90 days and a 1 year total shareholder return...
SEHK:9969
SEHK:9969Biotechs

Is InnoCare Pharma (SEHK:9969) Quietly Recasting Its Future Around Autoimmune Dermatology?

Earlier this month, InnoCare Pharma received CDE approval in China to begin a Phase II/III trial of its novel TYK2 inhibitor soficitinib for chronic spontaneous urticaria, expanding its autoimmune and dermatology pipeline. This move deepens InnoCare’s push beyond oncology into chronic inflammatory skin diseases, targeting a large, under-served CSU patient population in China that requires long-term treatment. We’ll now examine how advancing soficitinib into Phase II/III for chronic...
SEHK:1
SEHK:1Industrials

How China’s New Oversight of Overseas Port Sales Will Impact CK Hutchison Holdings (SEHK:1) Investors

Earlier this week, China’s Ministry of Commerce announced it would review and supervise CK Hutchison Holdings’ overseas port asset sales to ensure fair competition and protect national sovereignty, security, and development interests. This added layer of Chinese regulatory oversight introduces fresh uncertainty around the timing and structure of CK Hutchison’s port divestments, potentially affecting how investors assess its portfolio reshaping efforts. Next, we’ll examine how this new...
SEHK:881
SEHK:881Specialty Retail

Does Zhongsheng Group Holdings’ (SEHK:881) New Audit Chair Reshape Its Governance Risk Profile?

Earlier this week, Zhongsheng Group Holdings announced that long-serving independent non-executive director and audit committee chair Mr. Ying Wei resigned on 19 December 2025, with tax specialist Mr. Bai Fengjiu appointed to both roles the same day. Alongside these board changes, the company published detailed board and committee compositions, giving investors clearer visibility into its governance and oversight structure. We’ll now examine how the refreshed audit committee leadership and...
SEHK:1088
SEHK:1088Oil and Gas

China Shenhua Energy (SEHK:1088): Valuation Check After Mixed November Coal and Chemical Performance Update

China Shenhua Energy (SEHK:1088) just released its November and year to date operating update, with softer coal volumes but stronger polyethylene and polypropylene sales, giving investors a mixed read on the company’s core and chemical businesses. See our latest analysis for China Shenhua Energy. The stock has been resilient despite softer coal numbers. The latest HK$39.68 close underpins a 21.9% year to date share price return and a standout 36.9% one year total shareholder return,...
SEHK:2282
SEHK:2282Hospitality

Will Elevating Veteran Insider Kenneth Feng To CEO Reshape MGM China Holdings' (SEHK:2282) Macau Narrative

MGM China Holdings has appointed long-serving executive Kenneth Xiaofeng Feng as chief executive officer, effective December 19, 2025, after more than two decades in varied finance, operations and development roles across the MGM group. By elevating its president and executive director, with deep international operations and audit committee experience, to a three-year CEO term, the board is signaling confidence in continuity and execution-focused leadership for its Macau business. We’ll now...
SEHK:1378
SEHK:1378Metals and Mining

Taking Stock of China Hongqiao Group (SEHK:1378) After Its Inclusion in the Hang Seng China Enterprises Index

China Hongqiao Group Added to a Key Benchmark China Hongqiao Group (SEHK:1378) just joined the Hang Seng China Enterprises Index. This shift can pull in institutional money and passive index tracking capital, subtly reshaping the stock’s demand dynamics. See our latest analysis for China Hongqiao Group. The inclusion comes after a powerful run, with the latest share price at HK$31.7 and a year to date share price return of 178.56%, backed by a 1 year total shareholder return of 193.30% that...
SEHK:700
SEHK:700Interactive Media and Services

Tencent (SEHK:700) Valuation Check After Gaming Surge and Nvidia Cloud Workaround Boost Growth Prospects

Tencent Holdings (SEHK:700) is back in focus after China’s video game industry hit a new revenue high, while the company quietly tapped Japanese cloud partners to access Nvidia Blackwell chips despite ongoing US export controls. See our latest analysis for Tencent Holdings. Those themes are already feeding into sentiment, with the share price up strongly on a year to date basis and a solid one year total shareholder return suggesting momentum is still broadly constructive rather than...